How Can I Manage Thrombocytopenia in Hemodialysis Patient? A Review

Ther Apher Dial. 2020 Aug;24(4):352-360. doi: 10.1111/1744-9987.13448. Epub 2019 Dec 2.

Abstract

Hemodialysis (HD) is the most important treatment for patients with end-stage renal disease (ESRD). Thrombocytopenia is a potential treatment complication related to dialysis. Under normal circumstances, the platelet count would slightly decrease within the first hour of HD, but get restored towards the end of procedure. In most patients, the platelet count can be maintained within the normal range, and the occurrence of thrombocytopenia is relatively rare in clinical practice. Therefore, the possibility of thrombocytopenia in HD patients is often ignored. Moreover, thrombocytopenia might be misdiagnosed and mistreated. At present, almost all articles on the subject, apart from some case reports, focus on pseudothrombocytopenia and heparin-induced thrombocytopenia. In this review, we summarized various underlying causes, mechanisms, and diagnostic approaches to thrombocytopenia in HD patients. The review aims to provide a guide for clinicians interested in the causes and adequate treatment of thrombocytopenia.

Keywords: Hemodialysis; Heparin-induced thrombocytopenia; Pseudothrombocytopenia; Thrombocytopenia.

Publication types

  • Review

MeSH terms

  • Anticoagulants / adverse effects*
  • Antiphospholipid Syndrome / complications*
  • Antiphospholipid Syndrome / therapy
  • Disease Management
  • Humans
  • Infections / complications*
  • Infections / therapy
  • Platelet Transfusion
  • Renal Dialysis / adverse effects*
  • Renal Dialysis / methods
  • Thrombocytopenia / chemically induced
  • Thrombocytopenia / etiology*
  • Thrombocytopenia / therapy*

Substances

  • Anticoagulants